Condition
Severe, refractory Sjogren’s disease with organ involvement
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Rapcabtagene Autoleucel
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Active Not Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Rapcabtagene Autoleucel1
Active Sponsors
- Novartis Pharmaceuticals1
- Novartis Pharma AG1
Related Conditions
- Difficult To Treat Rheumatoid Arthritis1
- Rheumatoid Arthritis Ra And Sjögrens Disease Sjd1